A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Glenn J HannaMyung-Ju AhnJameel MuzaffarBhumsuk KeamDaniel W BowlesDeborah J WongAlan L HoSung-Bae KimFrancis P WordenTak YunXianzhang MengJan M Van TornoutMaureen G ConlanHyunseok KangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In patients with progressing R/M ACC, rivoceranib demonstrated anti-tumor activity and a manageable safety profile consistent with other VEGFR TKIs.